Option Care Health (NASDAQ:OPCH) Price Target Raised to $38.00 at Morgan Stanley

Option Care Health (NASDAQ:OPCH) had its price objective increased by analysts at Morgan Stanley from $35.00 to $38.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price objective indicates a potential upside of 8.08% from the stock’s previous close.

A number of other analysts have also recently commented on the stock. Stephens upgraded shares of Option Care Health to a “strong-buy” rating in a research note on Thursday, December 11th. Citizens Jmp reissued a “market outperform” rating and set a $38.00 price objective (up previously from $36.00) on shares of Option Care Health in a research note on Tuesday. Deutsche Bank Aktiengesellschaft raised their target price on shares of Option Care Health from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. JMP Securities set a $36.00 price target on shares of Option Care Health in a report on Friday, October 31st. Finally, Cowen assumed coverage on shares of Option Care Health in a research report on Thursday, October 2nd. They set a “hold” rating on the stock. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.17.

Option Care Health Stock Up 9.7%

Shares of Option Care Health stock traded up $3.10 on Tuesday, hitting $35.16. The company had a trading volume of 1,620,755 shares, compared to its average volume of 1,952,414. The stock has a market capitalization of $5.58 billion, a price-to-earnings ratio of 27.88, a P/E/G ratio of 1.98 and a beta of 0.80. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.05 and a current ratio of 1.56. Option Care Health has a 1 year low of $24.24 and a 1 year high of $35.53. The stock has a 50 day moving average of $30.83 and a 200-day moving average of $29.40.

Insiders Place Their Bets

In other news, Director Harry M. Jansen Kraemer, Jr. purchased 38,000 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was acquired at an average cost of $25.98 per share, for a total transaction of $987,240.00. Following the purchase, the director directly owned 413,390 shares in the company, valued at $10,739,872.20. This trade represents a 10.12% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.64% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of OPCH. USA Financial Formulas bought a new position in Option Care Health during the second quarter valued at $26,000. Cornerstone Planning Group LLC grew its position in shares of Option Care Health by 7,621.4% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock worth $30,000 after buying an additional 1,067 shares in the last quarter. Advisory Services Network LLC purchased a new position in shares of Option Care Health during the third quarter valued at $35,000. McIlrath & Eck LLC bought a new stake in shares of Option Care Health in the second quarter valued at about $37,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Option Care Health in the third quarter worth about $38,000. Institutional investors own 98.05% of the company’s stock.

Key Option Care Health News

Here are the key news stories impacting Option Care Health this week:

• Positive Sentiment: Company raised FY-2025 and Q4-2025 guidance above Street expectations: FY-2025 EPS guide 1.720–1.760 vs. consensus ~1.640; Q4 EPS 0.460–0.490 vs. consensus ~0.440. Revenue guidance for FY-2025 and Q4 were in line with expectations (~$5.6B–$5.7B FY, ~$1.5B Q4). Positive EPS beats likely support the rally. Option Care Health Announces Preliminary Fourth Quarter & Full Year 2025 Financial Results and Preliminary Financial Guidance for Full Year 2026
• Neutral Sentiment: FY-2026 guidance mixed: EPS guide 1.820–1.920 slightly above consensus (~1.79), while revenue guidance of ~$5.8B–$6.0B is modestly below the ~$6.1B consensus — EPS strength is supportive, but lower revenue guidance could cap upside if growth concerns persist. Option Care Health Announces Preliminary Fourth Quarter & Full Year 2025 Financial Results and Preliminary Financial Guidance for Full Year 2026
• Positive Sentiment: Analyst support: Citizens/JMP reaffirmed a “market outperform” rating and raised the price target to $38 (from $36), implying roughly mid‑single-digit to low‑double‑digit upside vs. the current market price — analyst backing can boost investor confidence and buying interest. Benzinga
• Neutral Sentiment: Short interest data reported as a large increase but shows zero shares / NaN change — likely a data reporting glitch; not meaningful until accurate short-interest figures are published. Investors should wait for confirmed short-interest updates before drawing conclusions.

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.